Nanostructured lipid carriers as a potential vehicle for Carvedilol delivery: Application of factorial design approach

Patil, Ganesh B.; Patil, Nandkishor D.; Deshmukh, Prashant K.; Patil, Pravin O.; Bari, Sanjay B.

doi:10.3109/21691401.2014.909820

Cited by 56 publications

(19 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The pharmacokinetic studies of vinpocetine-loaded NLCs depicted augmented C max (1.918-fold) and AUC values (3.2-fold) in comparison to a drug suspension after single administration in Wistar rats [39]. In a similar manner, the encapsulation of carvedilol in NLCs having 110-nm size and 85.11% entrapment efficiency showed sustained release up to 30 h suggesting their applicability in overcoming its extensive metabolism [28]. …”

Section: Oral Bioavailability Enhancement By Nlcsmentioning

confidence: 99%

Nanostructured Lipid Carriers: Versatile Oral Delivery Vehicle

Poonia¹,

Kharb

Lather³

et al. 2016

Future Sci. OA

151

View full text Add to dashboard Cite

Oral delivery is the most accepted and economical route for drug administration and leads to substantial reduction in dosing frequency. However, this route still remains a challenge for the pharmaceutical industry due to poorly soluble and permeable drugs leading to poor oral bioavailability. Incorporating bioactives into nanostructured lipid carriers (NLCs) has helped in boosting their therapeutic functionality and prolonged release from these carrier systems thus providing improved pharmacokinetic parameters. The present review provides an overview of noteworthy studies reporting impending benefits of NLCs in oral delivery and highlights recent advancements for developing engineered NLCs either by conjugating polymers over their surface or modifying their charge to overcome the mucosal barrier of GI tract for active transport across intestinal membrane.

show abstract

Section: Oral Bioavailability Enhancement By Nlcsmentioning

confidence: 99%

Nanostructured Lipid Carriers: Versatile Oral Delivery Vehicle

Poonia¹,

Kharb

Lather³

et al. 2016

Future Sci. OA

151

View full text Add to dashboard Cite

show abstract

“…Because of their solid lipid matrix, controlled release from these carriers is possible. In recent years, NLC, as a mature novel pharmaceutical form have been widely applied into dermal drug delivery system (Muller et al 2011, Patil et al 2016, Tichota et al 2014.…”

Section: Introductionmentioning

confidence: 99%

Optimization of nanostructured lipid carriers for topical delivery of nimesulide using Box–Behnken design approach

Moghddam

Ahad

Aqil

et al. 2016

Artificial Cells, Nanomedicine, and Biotechnology

View full text Add to dashboard Cite

show abstract

“…Stability Studies: To ensure the stability of prepared nano-lipid carriers to withstand environmental stress, the stability study was conducted as per ICH guidelines (Q1AR2) 12 . NLCs were stored at normal condition, i.e., room temperature (25 ± 2C, º60 ± 5% RH) and accelerated temperature (40 ± 2 ºC, 75 ± 5% RH) for 180 days.…”

Section: Ex-vivo Diffusion Studymentioning

confidence: 99%

Untitled

2019

IJPSR

View full text Add to dashboard Cite

The aim of the present work was to develop and evaluate the potential of nanostructured lipid carriers (NLCs) loaded with Clobetasol-17-propionate (CP) as a new approach for the topical treatment of psoriasis. CP-loaded NLCs were prepared by melt emulsification and ultra-sonication method and optimized using 3 3 full factorial designs (Design-Expert software 11.0), by using solid lipid (compritol ATO 888) and liquid lipid (oleic acid) and Tween 80 as a surfactant. Drug loaded NLCs were evaluated for various parameters like particle size, surface charge, polydispersity index, entrapment efficiency, surface morphology, thermal analysis, in-vitro drug release through the skin (Franz diffusion cell), drug deposition study and stability. The optimized formulation has a particle size of 91.2 ± 2.37 nm, the zeta potential of -34.7 ± 1.49 mV, polydispersity index of 0.173 ± 0.035 and entrapment efficiency of 85.4 ± 2.89%. Release study demonstrated prolonged CP release from NLCs following Higuchi release kinetics with r 2 = 0.9838, while pure CP suspension showed quicker drug release obeying zero-order kinetics with r 2 value of 0.9904. Skin permeation study of CP loaded SLNs suspension showed prolonged drug release up to 24 h. The maximum ex-vivo drug deposition was obtained after developing the drug into NLCs (51.23 µg/ml) when compared to the pure drug (18.34 µg/ml). The prepared NLCs based formulation has proved to be a promising carrier system for the treatment of psoriasis.

show abstract

Nanostructured lipid carriers as a potential vehicle for Carvedilol delivery: Application of factorial design approach

Cited by 56 publications

References 21 publications

Nanostructured Lipid Carriers: Versatile Oral Delivery Vehicle

Nanostructured Lipid Carriers: Versatile Oral Delivery Vehicle

Optimization of nanostructured lipid carriers for topical delivery of nimesulide using Box–Behnken design approach

Untitled

Contact Info

Product

Resources

About